iStock; Skye Gould/Insider
This story is available exclusively to Insider subscribers.
Become an Insider and start reading now.
At least 6 biotech startups launched in the past year after creating or acquiring smaller ventures.
These "mega biotechs" are fueled by record amounts of VC flowing into the drug industry.
Insiders say they are "priced for perfection" and could fail to live up to their early valuations.
To understand the hottest new trend in biotech, take a look at the firm Centessa Pharmaceuticals.
Centessa was formed just seven months ago by the life-sciences venture-capital firm Medicxi, which fused together 11 startups.
These startups likely would have been harder to finance as independent entities, said Perceptive Advisors' Chris Garabedian and another venture capitalist who was not authorized to speak to the media (Neither had inside knowledge of the deal, and both said their assessment was based on their experience as biotech VCs). Medicxi likely wanted to dress them up to create a more attractive investment opportunity.